
Opinion|Videos|September 17, 2024
Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact
Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs?
- How do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will affect access to oral HMAs starting in 2025?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD
3
AI Reshaping Diabetes Care From Nutrition to Clinical Decisions
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5
